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Background: Oral cavity and oropharynx cancer are increasing in incidence worldwide but survival outcomes have
not significantly improved over the last three decades. The presence of dysplasia or carcinoma in situ at surgical
margins following resection of squamous carcinoma of the mucosal surfaces of the head and neck has been shown
to be associated with a higher incidence of local recurrence and reduced survival. While invasive carcinoma in
mucosal surfaces can usually be distinguished from adjacent normal mucous membrane, pre-malignant disease is
much less readily distinguished at operation. We describe a protocol for a randomised, controlled trial in which we
will assess the effectiveness of Lugol’s iodine staining in allowing visualisation and excision of cancer margin
dysplasia at time of primary surgery.
Methods/Design: We will recruit 300 patients diagnosed with oral cavity or oropharynx squamous cell carcinoma.
All participants will be planned for primary surgery with curative intent. After completion of baseline assessment
participants will be randomised into either a standard surgical treatment arm or surgical treatment including Lugol’s
iodine staining.
Discussion: This paper describes the rationale and design of a unique trial in head and neck surgical oncology. If
margin dysplasia visualisation with Lugol’s iodine allows complete excision of high-risk, pre-cancer mucosa at time
of primary surgery, this may lead to a reduction in local recurrence and improved survival.
Trial registration: Current Controlled Trials ISRCTN03712770.
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Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Provision of written
informed consent
Previous surgery, chemotherapy or
radiotherapy for head and neck cancer
Men and women
aged >18 years
Allergy to iodine
Histologically proven squamous
cell carcinoma of the oral cavity
or oropharynx
Distant metastases (positive neck nodes
are not an exclusion)
Planned for primary surgical
treatment with curative intent
Nasal, nasopharyngeal or
occult primary carcinoma
Previous diagnosis of cancer
in the past 5 years
(except basal cell carcinoma or
carcinoma of the cervix in situ).
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The presence of dysplasia or carcinoma in situ at surgical
margins following resection of carcinoma of the mucosal
surfaces of the head and neck, has been shown to be associ-
ated with a higher incidence of local recurrence events [1,2].
While invasive carcinoma in mucosal surfaces can usually
be distinguished from adjacent normal mucous membrane,
pre-malignant disease is much less readily distinguished at
operation. The mucosal surfaces of the head and neck are
not unique in this respect. Attempts to improve the identi-
fication of early carcinoma and intraepithelial neoplastic
change using adjunctive techniques are employed in the
cervix, large bowel and oesophagus. These include acetic
acid topical application, contact endoscopy, auto fluores-
cence and the use of Lugol’s iodine [3]. None of these has
been subject of evaluation in a clinical trial setting in head
and neck cancer.
Extensive literature exists regarding the use of Lugol’s
iodine, including use as an aid to the identification of neo-
plasia of the squamous epithelium of the oesophagus. The
structure of the mucosal surfaces of the mouth and oro-
pharynx are very similar to the proximal oesophagus and
the risk factors for neoplastic transformation at these sites
are similar. Lugol’s iodine visualisation of dysplastic mu-
cosa is employed in management of oesophageal disease
[4-8]. There is, however, a very limited literature describ-
ing the use of Lugol’s iodine in the management of head
and neck mucosal neoplasia and there are no reported
clinical trials [8-10].
The majority of the oral cavity and oropharynx is cov-
ered by stratified, non-keratinising, glycogen-containing
squamous epithelium. It is opaque, has multiple (15 to 20)
layers of cells and appears pale pink in colour on visual
examination. The intermediate and superficial layer cells
contain glycogen in their cytoplasm. In contrast, dysplastic
and invasive cancer cells contain little or no glycogen. This
is thought to be due to the Warburg effect of increased
cytosol glycolysis consequent to the genomic chaos seen
in the cancer cell.
Iodine is glycophilic and forms tri-iodide molecules
within the glycogen polymer spiral. This results in choc-
olate brown staining of normal non-keratinised oral and
oropharyngeal mucosa. Areas of dysplasia and invasive
cancer do not take up iodine as they lack glycogen and ap-
pear as pale coloured areas.
Heavily keratinised areas of the mouth such as the at-
tached gingivae and hard palate do not avidly take up
Lugol’s iodine. Respiratory mucosa also does not contain
glycogen and does not stain. Thus detailed head and neck
surgical anatomy knowledge is necessary in interpreting
the information gained with Lugol’s staining. The major
cancer sub-sites within the oral cavity and oropharynx are
lined with glycogen containing and therefore Lugol’s iod-
ine staining sites.The presence of mucous on the surface interferes with
the absorption of Lugol’s iodine. This can be minimised by
the use of 1.25% carbocisteine solution prior to Lugol’s
iodine.
Occasional mild adverse reactions have been reported
[11], but our pilot and feasibility studies have shown that
the use of mucosal epithelial staining with Lugol’s iodine is
a safe technique, which is simply accomplished. With a
short period of familiarisation it is readily adopted by ex-
perienced surgeons, is inexpensive, and seems likely to be
effective. We believe that a trial demonstrating a clear
benefit would have a substantial impact on clinical prac-
tice worldwide because of the simplicity of the technique
and low cost.Methods/Design
Study population
This study is designed as a prospective, multicentre,
randomised controlled trial to assess the effectiveness of
Lugol’s iodine in assisting excision of moderate dysplasia,
severe dysplasia and carcinoma in situ at mucosal resec-
tion margins of oral and oropharyngeal squamous cell car-
cinoma. It fits into the standard practice of care for UK
Head and Neck Cancer, and patients who meet the eligi-
bility criteria (Table 1) and provide informed written con-
sent will be enrolled. Detailed information on benefits and
risks will be provided to study candidates to fully inform
them of the process. Ethics approval has been received
from NRES Committee Yorkshire & The Humber-Leeds
East (REC reference: 10/H1306/29).
Randomisation and blinding
Patients will be randomly assigned in a 1:1 ratio to the
Lugol’s or non-Lugol’s (control) group. Independent ran-
domisation will be via telephone to the Warwick Medical
School Clinical Trials Unit (WMSCTU). Computer-
generated random permuted blocks will be used; stratifica-
tion will be by treatment centre/surgeon, tumour site and
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surgical team; however, the patient will not be informed of
the treatment.
Data monitors, pathologists and external reviewers will
be blinded to treatment allocations. The chief investiga-
tor, surgeons and other healthcare professionals will be
blinded to all results.
The LIHNCS intervention is to be carried out in the-
atre during surgery.
The trial follows the pathway as shown in Figure 1 below:
Trial intervention and control
Patients in the intervention arm will have primary tumour
stained with Lugol’s iodine at time of resection in the op-
erating theatre. Those in the control arm will not have
Lugol’s staining. All other intraoperative procedures will
be the identical between trial and control arms.
The intraoperative standard operating procedure
(SOP) covers application of Lugol’s iodine, tumour vol-
ume measured by volume displacement, and prepar-
ation of resected tumour for histopathology. It must be
followed for all trial patients and is supplied below.
Lugol’s iodine staining technique
Lugol’s Iodine staining to be performed under general
anaesthetic using good retraction, light and assistance.
1. Tumour area irrigated with 0.9% saline.
2. Tumour area irrigated with 20 mL Carbocisteine
(125 mg/5 mL).Figure 1 LIHNCS trial flowchart.3. Tumour area irrigated with 0.9% saline.
4. Tumour area irrigated with 20 mL of 1% Lugol’s iodine
(4 mL elemental iodine/potassium iodide + 16 mL 0.9%
saline) allowing a minimum of 30 s for staining to
occur before aspirating excess fluid.
5. Tumour area irrigated with 0.9% saline.
6. Staining procedure may be repeated until staining is
adequate.
7. Tumour resection planned to include a 1 cm
oncologically safe margin and areas of non-stained
mucosa where feasible.
Tumour volume to be measured by volume displacement
1. Standard 250 mL laboratory measuring cylinder
filled with sufficient 0.9% saline to completely
submerge the tumour sample that is to be
measured.
2. Resected tumour added and tumour volume
determined by volume displacement.
3. Record volume displaced on Surgery CRF form.
Preparation of resected tumour for histopathology
1. Primary specimen to be sutured to an appropriate
platform (gamgee or corkboard) to allow appropriate
display of resected specimen and accurate margin
assessment.
2. Specimen to be sent to pathology as per standard
site procedures.
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Resected tumour samples will be analysed locally using
recruiting site standard protocols. Slides and the accom-
panying pathology report are then sent to the trial co-
ordinator where they are anonymised before being sent
for central pathology review.
As part of a quality assurance process a central pathology
review of all samples will be undertaken, performed by the
trial pathologist. All external samples will be re-reported
according to the Royal College of Pathologists minimum
dataset for head and neck carcinoma histopathology.
In addition to this dataset, the central pathologist will
report on the incidence of mild and moderate at muco-
sal resection margins in addition to severe dysplasia and
carcinoma in situ. The minimum dataset from primary
site pathology reporting will already report severe dys-
plasia and carcinoma in situ. Samples from the Bradford
Teaching Hospitals NHS Foundation Trust will also be
reviewed, as the purpose of the quality assurance of a
national spread of samples is to standardise all reports
against the reviewing pathologist.Table 2 Secondary outcomes
Secondary outcome measures:Follow-up protocol
The trial duration is expected to take 4 years in total.
Patients will be recruited over a 2-year period and will
be followed up for a minimum of 2 years.
Quality of Life (QoL) questionnaires and CRFs will be
completed at set time points (Figure 1) when the patient
attends for their routine clinic appointments. QoL will
be measured using the EORTC QLQ-30 and H&N dis-
ease specific EORTC QLQ-35 module questionnaires.
Swallowing-related QoL will be measured using the MD
Anderson Dysphagia Inventory (MDADI) questionnaire.
It is possible that since more tumours are likely to be
removed in the Lugol’s iodine arm, there may be an ef-
fect on functionality and quality of life.
At each time point, each domain of each questionnaire
will be compared between groups by ACNOVA, that is, lin-
ear regression with the follow-up score as the dependent
variable, group as the predictor and baseline score as the
covariate. Differences between groups will be calculated
along with 95% confidence intervals (CI) and P values.1. Acceptability of the technique to surgeons carrying out surgery for
oral and oropharyngeal carcinoma.
2. Effect of Lugol’s technique on any further treatment carried out
(radiotherapy, chemoradiotherapy or further surgery).
3. Estimate of the two-year locoregional recurrence rates in each group.
4. Mean and range of volume of tissue removed by each method.
5. Safety of the technique.
6. Assessment of quality of life changes using EORTC QLQ-30 and
EORTC-35 H&N questionnaires, and the MD Anderson Dysphagia
Inventory (MDADI) questionnaire
7. Overall survivalSafety and adverse event reporting
In accordance with Good Clinical Practice for Research
guidelines the occurrence of adverse events will be mon-
itored carefully and recorded in detail during the course
of the clinical trial.
If during that time a serious adverse event (SAE) is
thought to be related to involvement in the trial and is
unexpected the trial office will report this event to the
Multicentre Research Ethics Committee (MREC).The Principal Investigator in each centre must report
any SAEs to the trial coordinator within 24 h of aware-
ness of it. The SAE form will be completed and faxed to
the trial coordinator who will then liaise with the Chief
Investigator to compile all necessary information. The
trial office will be responsible for reporting SAEs to the
Sponsor and MREC within the required timelines.Study endpoints
The primary outcome measure will be rate of surface
dysplasia, carcinoma in situ or carcinoma at surface mu-
cosal margins in the Lugol’s-treated group versus gold
standard management control arm. Secondary endpoints
are detailed in Table 2.
Secondary outcomes
The primary endpoint of the presence of dysplasia in the
resection margins will be compared using Pearson’s chi-
squared test when all 300 patients have been recruited.
There will be planned sub-group analysis by T stage to as-
sess the effect of tumour size. T1 and T2 primary cancers
will be compared with T3 and T4 cancers. There will be a
pre-planned interim analysis when the first 164 patients
have been recruited in order to assess whether the as-
sumptions made in the power calculations hold true.
The total sample size is to be 300 patients, with an es-
timated recruitment rate of 15 patients per site per year
over a 2-year period.
Sample size calculation
In an initial study of two series of 50 consecutive pa-
tients having resection of oral or oropharyngeal SCC
32% in the standard group and 4% in the Lugol’s iodine
group had dysplasia, carcinoma in situ or invasive SCC
at a surgical margin (McMahon et al., 2012).
The primary outcome measure is rate of dysplasia of
any grade at excision margins. We calculated that to de-
tect a reduction from 30% in the control group (as in the
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with 90% power at a two-sided significance level of 0.05,
the number of patients required in each group is 82. The
rate for the control arm may be a little lower. If it is 20%
then a similar proportionate reduction to 7% would re-
quire 144 in each group. We propose to randomise 150 to
each group, 300 patients in total. However, should the
proportion of dysplasia positive cases change from 17%
(control) to 4% in the Lugol’s group, then the power calcu-
lation would require 100 patients in each group for 80%
power and 130 patients in each group for 90% power. We
therefore aim to continue planning for recruitment of 300
patients overall and 150 in each group.
The recurrence rate in the dysplasia group is estimated
at 33% [1]. To detect a difference of 25% in 20% of the pa-
tients (that is, those who convert from involved margins
to non-involved as a result of the intervention), it is neces-
sary to detect a difference of 5% overall and a much larger
study would be needed (even with alpha = 0.1 and one-
sided test over 1,200 patients would be needed).
Instead we will estimate a 95% CI for the hazard ratio.
Discussion
The Head and Neck Cancer research literature contains
very few well-designed trials and there are no published
trials in surgical oncology regarding primary surgery for
cancer at this site.
Our cohort study data show a reduction in margin dys-
plasia using Lugol’s iodine at cancer resection from 32%
for control to 4% for intervention groups [12]. Our feasi-
bility study showed very high patient acceptance rates (un-
published data) and we are very optimistic that this trial
will recruit participants.
We are very fortunate to have the support of the CTAAC
of Cancer Research UK and hence NIHR portfolio status
for this study. This provides support from the Clinical
Research Network (CRN) and has enabled LIHNCS to reach
a wider audience and undoubtedly helped in enhancing
recruitment to this trial to date.
Trial status
Open and recruiting.
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